Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

Core Points - Idorsia Ltd has announced the date for its Annual General Meeting (AGM) to be held on May 28, 2025, to approve the Annual Report for the year ending December 31, 2024 [1] - The Chairman of the Board, Jean-Paul Clozel, expressed gratitude towards the Board members and noted that Dr. Sophie Kornowski will not seek re-election, while all other members will stand for re-election [2] - The company aims to amend its Articles of Association regarding share capital to enhance financing flexibility [2] Company Overview - Idorsia Ltd is focused on discovering, developing, and commercializing transformative medicines, with a strong scientific core and a commitment to challenging accepted medical paradigms [6][8] - The company is headquartered near Basel, Switzerland, and is positioned within a European biotech hub, emphasizing its capabilities in drug discovery, particularly in small-molecule drugs [7][8] AGM Agenda Highlights - The AGM will include votes on the Annual Report 2024, Consolidated Financial Statements 2024, and Statutory Financial Statements 2024 [7] - Other key agenda items include the appropriation of available earnings, discharge of the Board of Directors, amendments to share capital, and re-elections of Board members and statutory auditors [7]